Акции Avenue Therapeutics упали на 21,7% из-за резкого снижения объема торгов

Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) traded down 21.7% on Monday . The stock traded as low as $0.4520 and last traded at $0.4520. Approximately 308 shares were traded during mid-day trading, a decline of 95% from the average session volume of 6,020 shares. The stock had previously closed at $0.5770. Avenue Therapeutics Stock Performance The stock has a market capitalization of $1.49 million, a P/E ratio of 0.02 and a beta of -0.20. The stock has a 50-day moving average price of $0.31 and a two-hundred day moving average price of $0.32. Avenue Therapeutics Company Profile Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery. The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain. Featured Stories Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.